Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug-Drug Interaction Study of Vesatolimod in HIV
NCT05458102Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Aug 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vesatolimod in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity and 11 more. Started Aug 2022; status: terminated.
02
Drugs
vesatolimod
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05458102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05458102.